测试版
试验雷达 AI
临床试验 NCT06851832 针对带状疱疹,Herpes Zoster Vaccine目前招募中。请查看临床试验雷达卡片视图和 AI 发现工具了解所有详情,或在此提出任何问题。
一个试验符合筛选条件
卡片视图

Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older

招募中
临床试验详情主要以英语提供。然而,试验雷达 AI可以提供帮助!只需点击“解释临床试验”即可查看和讨论您选择的语言的试验信息。
临床试验NCT06851832旨在研究预防,主要针对带状疱疹,Herpes Zoster Vaccine。这是一项I期 (第一期) II期 (第二期) 干预性研究试验,目前试验状态为招募中。试验始于2025年2月16日,计划招募960名患者。该研究由Ab&B Bio-tech Co., Ltd.JS主导,预计于2028年9月16日完成。试验数据来源于ClinicalTrials.gov,最后更新时间为2025年3月3日
简要概括
The objective of this study was to evaluate the safety, immunogenicity and immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and older.
官方标题

A Phase I/II Clinical Trial with Randomized, Blinded, Controlled Design to Evaluate the Safety and Immunogenicity of the Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Populations Aged 40 Years and Older Post -vaccination

疾病
带状疱疹Herpes Zoster Vaccine
其他研究标识符
  • VZV-ZHSW-01
NCT编号
实际开始日期
2025-02-16
最近更新发布
2025-03-03
预计完成日期
2028-09-16
计划入组人数
960
研究类型
干预性研究
试验分期 (阶段)
I期 (第一期)
II期 (第二期)
试验状态
招募中
主要目的
预防
分配方式
随机
干预模型
平行
盲法
双盲
试验组/干预措施
参与者组/试验组干预措施/治疗方法
实验性Recombinant zoster Vaccine (CHO cell) (low adjuvant)
It is used for vaccination of experimental vaccine group A subjects in phase I and II clinical trials
Recombinant Zoster Vaccine(CHO Cell)(Low Adjuvant)
The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 50 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
实验性Recombinant zoster Vaccine (CHO cell)
It is used for vaccination of experimental vaccine group B subjects of phase I clinical trial , experimental vaccine group B1 and B2 subjects of phase II clinical trial
Recombinant Zoster Vaccine (CHO Cell)
The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle. Vaccination Schedule 1: A total of two doses will be given, with the second dose administered 30 days after the first dose. Vaccination Schedule 2: A total of two doses will be given, with the second dose administered 60 days after the first dose \[only applicable to the Phase II Experimental Vaccine Group B2\].
阳性对照Zoster Vaccine, Live
It is used for vaccination of positive control group A1 and A2 subjects in phase Ⅱ clinical trial
Zoster Vaccine, Live
The dosage for each administration is 0.5 mL, containing not less than 4.3 lg PFU of varicella-zoster live virus, administered subcutaneously at the attachment site of the lower edge of the deltoid muscle on the outer side of the upper arm. A total of one dose will be given. To maintain blinding, the positive control group A1 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 30. The positive control group A2 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 60.
阳性对照Recombinant Zoster Vaccine (CHO cell)
It is used for vaccination of positive control group B subjects in phase Ⅱ clinical trial
Recombinant Zoster Vaccine (CHO Cell)
The dosage for each administration is 0.5 mL, containing 50 μg of gE and the AS01B adjuvant system \[QS-21 (50 μg), MPL (50 μg), DOPC (1 mg), and cholesterol (0.25 mg)\], administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 60 days after the first dose.
安慰剂对照Recombinant Zoster Vaccine (CHO cell) (Adjuvant control)
It is used for vaccination of adjuvant control group subjects in phase Ⅰ clinical trial
Recombinant Zoster Vaccine (CHO Cell) (Adjuvant Control)
The dosage for each administration is 0.5 mL, containing 0.25 mL of MF59 and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
安慰剂对照normal saline
Used in phase Ⅰ clinical trial; To maintain blinding, positive control group A1 and positive control group A2 received placebo on day 0 (for phase II clinical trial).
生理盐水
The dosage for each administration is 0.5 mL, containing 0.5 mL of NaCl solution, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose (applicable to Phase I clinical trial). To maintain blinding, subjects in the positive control A1 and positive control A2 groups will receive a placebo on Day 0 (applicable to Phase II clinical trial).
主要终点
结果指标度量标准描述时间框架
The incidence of solicited local and systemic adverse events (AEs) within 0-14 days after each vaccine dose.
Within 14 days after each vaccine dose.
The incidence of unsolicited adverse events (AEs) within 0-30 days after each vaccine dose.
Within 30 days after each vaccine dose.
The incidence of laboratory abnormalities (including blood biochemistry, blood routine, urine routine and electrocardiogram) on Day 3 after each vaccine dose.
On Day 3 after each vaccine dose.(Applicable to Phase I only)
The incidence of serious adverse events (SAEs) and Adverse Events of Special Interest (AESI) from the vaccination of the first dose to 12 months after full immunization.
From the vaccination of the first dose to 12 months after full immunization.
The cell-mediated immune response rate of CD4+ T cells expressing at least two activation markers (IFN-γ, IL-2, TNF-α, CD40L) one month after full immunization.
Detected using intracellular cytokine staining (ICS) by flow cytometry
One month after full immunization.(Applicable to Phase Ⅱ only)
The GMC/GMT, seroconversion rate, and GMI of anti-gE antibodies and anti-VZV antibodies one month after full immunization.
Detected using enzyme-linked immunosorbent assay (ELISA).
One month after full immunization.(Applicable to Phase Ⅱ only)
次要终点
结果指标度量标准描述时间框架
The GMC/GMT, seroconversion rate, and GMI of anti-gE antibodies and anti-VZV antibodies at 6, 12, 24, and 36 months after full immunization.
Detected using enzyme-linked immunosorbent assay (ELISA)
At 6, 12, 24, and 36 months after full immunization.(Applicable to Phase Ⅱ only)
The cell-mediated immune response rate of CD4+ T cells expressing at least two activation markers (IFN-γ, IL-2, TNF-α, CD40L) before the second dose and at 6, 12, 24, and 36 months after full immunization.
Detected using intracellular cytokine staining (ICS) by flow cytometry
Before the second dose and at 6, 12, 24, and 36 months after full immunization(Applicable to Phase Ⅱ only)
资格标准

适龄参与研究
成人, 老年人
最低年龄要求
40 Years
适龄性别
全部
接受健康志愿者
  • Male or female participants aged 40 years or older at the time of enrollment.
  • Voluntarily agrees to participate in the trial, fully understands, and signs the informed consent form.
  • Able to attend all scheduled follow-ups and comply with the clinical trial protocol requirements to complete the trial.
  • Female participants must meet the following criteria:1)Surgically sterilized or postmenopausal for ≥2 years, or women of childbearing potential (not menopausal or menopausal <2 years) with a negative pregnancy test and willing to use effective physical contraception (e.g., condoms, intrauterine device) from enrollment until 6 months after full immunization. 2)Agree not to breastfeed from enrollment until 6 months after full immunization.
  • Axillary temperature ≤37.0°C.

a Exclusion criteria for the first dose:

  • A history of herpes zoster.
  • A history of varicella or herpes zoster vaccination.
  • Close contact with a varicella/herpes zoster patient within the past year.
  • Received immunoglobulin and/or any blood products within 3 months before vaccination.
  • Received immunosuppressive treatment within 3 months prior to vaccination (e.g., systemic corticosteroids for ≥14 days, at a dose ≥2 mg/kg/day or ≥20 mg/day of prednisone, or an equivalent dose of prednisone) (excluding inhaled, intra-articular, and topical steroids).
  • A history of severe allergic reactions to any vaccine or medication (e.g., anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reactions, severe urticaria, etc.), or a family history of severe allergies.
  • Immunocompromised or diagnosed with congenital or acquired immune deficiency diseases, or infected with Human Immunodeficiency Virus (HIV).
  • A history of seizures, epilepsy, encephalopathy (such as congenital brain malformation, brain trauma, brain tumors, cerebral hemorrhage, cerebral infarction [except for infarction without sequelae or lacunar infarction], brain infections, or brain damage caused by chemical drug poisoning), or psychiatric disorders, or a family history of psychiatric disorders; or other serious neurological diseases.
  • Inadequate time interval between vaccination and other vaccines (e.g., inactivated or recombinant subunit vaccines within 14 days prior to vaccination, live attenuated vaccines, viral vector vaccines, or mRNA vaccines within 28 days prior to vaccination).
  • Acute illness or an acute exacerbation of a chronic disease within 3 days prior to vaccination, or use of antipyretic, analgesic, or antihistamine medications within 3 days prior to vaccination.
  • Suffering from severe infectious skin diseases.
  • Ongoing or long-term alcohol and/or drug abuse history (Note: for the past three months, males drinking more than 14 standard drinks per week, females more than 7 standard drinks per week. One standard drink contains 14g of alcohol, equivalent to 360mL of beer, 45mL of liquor at 40% alcohol, or 150mL of wine. Drug abuse refers to the repeated or excessive use of drugs with dependence potential unrelated to recognized medical needs, for non-medical purposes).
  • A history of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection.
  • Severe liver or kidney disease, complications from diabetes, severe cardiovascular diseases, or uncontrolled hypertension despite medication.
  • Asplenia or functional asplenia, or any condition leading to splenectomy.
  • Abnormal laboratory test results before the first dose, deemed clinically significant by the investigator (only applicable to Phase I).
  • Currently participating in other experimental or unregistered clinical trials for products (drugs, vaccines, or devices), or planning to participate in another clinical trial before the end of this trial.
  • A history of hematologic or lymphatic system diseases, such as unexplained lymphadenopathy or hematolymphatic lymphoma.
  • A history of diagnosed potential immune-mediated diseases, autoimmune diseases, or Guillain-Barré syndrome.
  • Any other condition deemed by the investigator to be unsuitable for participation in this clinical trial.

a Exclusion criteria for the second dose:

  • Positive urine pregnancy test.
  • Grade 4 adverse events related to vaccination.
  • Severe allergic reactions occurring after vaccination.
  • New findings or newly occurring conditions that meet the exclusion criteria after the first dose, with the investigator determining whether to terminate the trial vaccine administration.
  • Other situations assessed by the investigator as requiring termination of vaccination.
Ab&B Bio-tech Co., Ltd.JS logoAb&B Bio-tech Co., Ltd.JS
Yither Biotechnology Co., Ltd logoYither Biotechnology Co., Ltd
研究中心联系人
联系人: Xue Zhao, Master, 18168168075, [email protected]
1 位于 1 个国家/地区的研究中心

Henan

Xiangcheng County Center for Disease Control and Prevention, Xuchang, Henan, China
Xue Zhao, Master, 联系人, 18168168075, [email protected]
Zhiqiang Xie, Master, 联系人
招募中